key: cord-0024354-y4vqc7ex
authors: Mungmunpuntipantip, Rujittika; Wiwanitkit, Viroj
title: ICU admission and favipiravir
date: 2021-10-22
journal: North Clin Istanb
DOI: 10.14744/nci.2021.60234
sha: 325ceaac0a7043eb1aa682f38738b703a8e3e37f
doc_id: 24354
cord_uid: y4vqc7ex

nan

To the Editor, We would like to share ideas on "ICU admission rates in Istanbul following the addition of favipiravir to the national COVID-19 treatment protocol" [1] . Guner et al. [1] concluded that "The addition of favipiravir to the national COVID-19 treatment protocol may explain this rapid decrease in the rate of ICU admissions and intubation". The favipiravir is the new hope for COVID-10 outbreak containment. However, the insufficiency and unavailability are main problems in many developing countries. The decreased ICU described by Guner et al. [2] might be an effect of favipiravir use. However, it might also be the effect by other factors such as other infectious disease control process, a good supportive treatment, and seasonal fluctuation of disease incidence. Finally, a recent report also showed that an additional use of hydroxychloroquine plus favipiravir can provide a better outcome than favipiravir alone.

Temporary cardiac pacing for fatal arrhythmia in living-donor liver transplantation: three case reports

Atrioventricular sequential pacing for hypertrophic cardiomyopathy during liver transplantation

Anesthetic management of a patient undergoing liver transplantation who had previous coronary artery bypass grafting using an in situ right gastroepiploic artery

ICU admission rates in Istanbul following the addition of favipiravir to the national COVID-19 treatment protocol

Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir